Hengrui's new anticancer drug Etan (apatinib) was launched on December 13

At the scene of aitan China listing meeting, the launching ceremony of aitan China listing meeting, i.e apatinib mesylate, is the only oral preparation targeted for advanced gastric cancer at present, and it is also proved to be a safe and effective oral drug after the failure of standard chemotherapy for advanced gastric cancer A large number of clinical studies show that aitan can significantly prolong the survival period of patients with advanced gastric cancer by inhibiting the formation of new blood vessels in tumor tissue A group photo of the guests of China listing conference of artan is one of the major new drug creation projects in the national "11th Five-Year plan" and "12th Five-Year plan" Its successful listing not only brings hope for patients with advanced gastric cancer, but also marks that the Chinese pharmaceutical enterprises represented by Hengrui pharmaceutical have embarked on a strategic development path from "imitation" to "innovation", which promotes the transformation of China from a "pharmaceutical power" to a "pharmaceutical power" At the same time, aitan is also the first small molecule anti angiogenesis targeted drug in the world that has been proved safe and effective after the failure of standard chemotherapy for advanced gastric cancer The success of the research and development of the drug marks that the pharmaceutical enterprises in China have embarked on a strategic scale development path from "imitation" to "innovation", which helps to promote the transformation of China from a "pharmaceutical power" to a "pharmaceutical power" It is understood that China's incidence rate of more than 40% of all gastric cancer patients in the world is far higher than that of countries such as Europe and the United States Because the early symptoms of the disease are not typical and routine gastroscopy is not popular, 60% - 80% of gastric cancer patients in China have reached the late stage The 5-year survival rate of patients with advanced gastric cancer is less than 20% Aitan is one of the national "11th Five Year Plan" and "12th Five Year Plan" major new drug creation projects, developed and produced by Jiangsu Hengrui Pharmaceutical Co., Ltd Qin Shukui, vice president of Nanjing Bayi Hospital of the PLA, and Li Jin, director of internal medicine of Fudan University Cancer Hospital jointly led the phase III clinical trial of aitan in the treatment of advanced gastric cancer, which was participated by 38 centers, further confirmed the effectiveness and safety of the drug in the treatment of advanced gastric cancer patients In the phase III study, 31 patients with advanced gastric cancer have survived 44 months with the drug At the same time, aitan, as an oral drug, is convenient to use, helps to improve patients' compliance, and greatly reduces the cost of treatment Qin Huaijin, director of the Department of science, technology and education of the national health and Family Planning Commission, said that now Chinese enterprises have a group of specialized new drug R & D talents with strong R & D ability and clear research direction, and national pharmaceutical enterprises are on the road of scientific research and innovation and have made some achievements According to statistics, there were about 950000 new cases of gastric cancer in the world last year, and China accounted for about half of them Gastric cancer is the second largest malignant tumor in China, and its mortality rate ranks the third among the top ten What's more, most of the patients are in the late stage of treatment, the existing treatment is limited, the prognosis is poor, and the 5-year survival rate is less than 20% The listing of apatinib will bring new gospel to many gastric cancer patients In a press conference, Jiangsu Hengrui Pharmaceutical Co., Ltd (hereinafter referred to as Hengrui pharmaceutical) announced that the new drug, apatinib, approved by the State Food and Drug Administration for the treatment of advanced gastric cancer, was officially on the market At present, epatinib mesylate is the only oral preparation of gastric cancer targeting drug According to Zhang Lianshan, deputy general manager of Hengrui pharmaceutical, as a class 1.1 new drug independently developed by domestic pharmaceutical companies, the price of aitan will be far lower than that of foreign pharmaceutical companies for the treatment of advanced gastric cancer after its listing, and aitan is an oral drug, which can be taken by patients at home, and the compliance of the drug will be better than the injection preparation that needs to go to the hospital Prior to its launch, apatinib carried out a large number of clinical studies In 2014, Qin Shukui, vice president of Nanjing Bayi Hospital of PLA, and Li Jin jointly led the clinical research results of apatinib in the treatment of advanced gastric cancer phase III, which was selected by the American Society of Clinical Oncology (ASCO) as the conference report and included in the best of ASCO paper in 2014 This is the first time that China's innovative drug research has made a conference report at the world's top academic conference, and has been selected into the excellent research of the annual conference for the first time It is understood that in 2015, the research results will also be published in the world's top authoritative medical journal, the lancet or the New England Journal of medicine Professor Qin Shukui pointed out that apatinib is a new small molecule targeting drug, more specifically, apatinib is a small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) Through highly selective competition for the ATP binding site of VEGFR-2 in cells, blocking the downstream signal transduction, inhibiting the formation of tyrosine kinase, thus inhibiting the formation of new blood vessels in tumor tissue, and finally achieving the purpose of tumor treatment At the same time, apatinib is the only small molecule targeted drug in the treatment of advanced gastric cancer after the failure of standard chemotherapy, which can significantly prolong the survival time of patients with advanced gastric cancer According to Zhou Yunshu, general manager of Hengrui pharmaceutical, aitan is a major new drug creation project of the 11th Five Year Plan and the 12th Five Year Plan, and the first new anti gastric cancer drug independently developed in China As a national pharmaceutical enterprise with a sense of social responsibility, Hengrui pharmaceutical plans to provide free use of aitan for a certain number of extremely poor patients every year In addition, we will also communicate with the hospital For those poor patients who have definite curative effect with aitan, we will not exclude the consideration of continuing to give medicine Gastric cancer is a high incidence disease with Chinese characteristics According to statistics, China accounted for 47% of the 952000 new cases of gastric cancer in 2013 The incidence rate of gastric cancer is second in China 352300 people die from gastric cancer every year, and the mortality rate is third Because the early symptoms are not typical and routine gastroscopy is not popular, 60% - 80% of gastric cancer patients in China have reached the late stage The 5-year survival rate of patients with advanced gastric cancer is less than 20% In recent decades, although a large number of human and material resources have been invested, no breakthrough has been made in the research and development of new drugs after the failure of standardized treatment for advanced gastric cancer, which leads to the lack of effective treatment for this kind of population, causing a great burden to patients, society and the country Therefore, the treatment of advanced gastric cancer needs more effective new treatment methods, which is also one of the original intention of Hengrui medical research and development of aitan The listing of aitan not only brings hope for the survival of the vast number of patients with advanced gastric cancer in China, but also represents Hengrui's practice of social responsibility as a representative of the innovation of national pharmaceutical enterprises Zhou Yunshu said that innovation is the forerunner of Hengrui's actions Hengrui will continue to undertake the mission of research and development of new frequently occurring drugs in China, work closely with international academic forces, actively explore the international development path of China's pharmaceutical science and technology industry, and strive to expand the life and health path of Chinese people.